Seaport Therapeutics reports positive phase 1 data for anxiety drug candidate

June 8, 2026 7:00 AM

Seaport Therapeutics Inc. (NASDAQ: SPTX) announced positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found